The Janus face of L-arginine supplementation in cardiovascular health and aging exploration of underlying mechanisms

Engineering notes

Key topics: autonomous driving, control. See the paper for implementation details and experimental results.

Chinese explanation / 中文解读

中文解读待补充：本站会优先为端到端自动驾驶、BEV感知、3D目标检测、轨迹预测、路径规划、LiDAR感知等高价值论文补充中文说明。

Original abstract

Since the discovery of L-arginine-nitric oxide (NO) pathway in control of cardiovascular function in 1980s, endothelial dysfunction characterized by decreased endothelial NO bioavailability is recognized as a critical hallmark of cardiovascular disease (CVD) and aging, L-arginine supplementation has been proposed as a potential therapeutic intervention primarily due to its role as the sole substrate for endothelial NO-synthase (eNOS). Although many experimental and clinical studies show improvement of endothelial functions by L-arginine supplementation, the beneficial effects could not be translated into the improvement of hard endpoint outcome. Even harmful effects such as worsening of endothelial function, cardiac function, and increased mortality in patients with advanced CVD are reported in the randomized clinical trials. Despite of the reported adverse effects in clinical trials, L-arginine intake is considered safe and is still widely used in our society to boost muscle mass in healthy and aged populations. While we believe that chronic L-arginine supplementation shall be carefully implemented in clinical settings or shall be avoided in patients with advanced CVD and aged population, future studies shall focus on investigation of the underlying mechanisms of the adverse effects of L-arginine supplementation. This is important not only for L-arginine supplementation but also for other amino acid supplementation aimed to improve cardiovascular health, particularly in the elderly population.

Links and sources

• PDF from original source

Comments